Wave (WVE) Reports Q1 2026 Earnings with Revenue Growth and Pipeline Advancements
Wave (WVE) reported Q1 2026 earnings with revenue of $38.2 million, driven by revenue recognition from regained WVE-006 rights and progress in its GSK collaboration. The company recorded a net loss of $26.1 million, down from $46.9 million in the prior year, and has a cash balance of $544.6 million, sufficient to fund operations through Q3 2028. Key pipeline developments include the initiation of a Phase IIa trial for WVE-007 and positive Phase I data showing fat reduction.
Tickers: $WVE
Topics: clinical trials earnings financial performance R&D expenses revenue